Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(15):1267-1269; doi:10.1093/jnci/91.15.1267
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nicholl, I. D.
Right arrow Articles by Dunlop, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicholl, I. D.
Right arrow Articles by Dunlop, M. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 15, 1267-1269, August 4, 1999
© 1999 Oxford University Press

EDITORIALS

Molecular Markers of Prognosis in Colorectal Cancer

Iain D. Nicholl, Malcolm G. Dunlop

Affiliations of authors: Colon Cancer Genetics Group, University of Edinburgh Division of Molecular and Clinical Medicine, and Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh, U.K.

Correspondence to: Malcolm G. Dunlop, M.D., Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU, U.K. (e-mail: Malcolm.Dunlop@hgu.mrc.ac.uk).

Characterization of molecular and cellular alterations involved in the initiation and progression of colorectal cancer is the focus of intense research activity, and this activity is not misdirected. In the United States, around 130 000 patients are diagnosed with colorectal cancer annually (1), and the incidence is rising rapidly in developing countries, particularly in Asia. Gaining new insight into the molecular pathogenesis of colorectal cancer will allow progress in many facets of disease control, including primary prevention on a population basis, identification of genetically predisposed groups for targeted surveillance and/or chemoprevention, prognosis for patients with established cancer, prediction of tumor response to treatment, and rational development of novel treatment approaches. Descriptive and mechanistic molecular studies of colorectal cancer are moving on apace, and we are now challenged with applying the wealth of available information for clinical benefit.

In this issue of the Journal, Halling et al. (2. . . [Full Text of this Article]

NOTE

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
F. Graziano and S. Cascinu
Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
Ann. Onc., July 1, 2003; 14(7): 1026 - 1038.
[Abstract] [Full Text] [PDF]